1. The TREK-1 potassium channel is involved in both the analgesic and anti-proliferative effects of riluzole in bone cancer pain.
- Author
-
Delanne-Cuménal M, Lamoine S, Meleine M, Aissouni Y, Prival L, Fereyrolles M, Barbier J, Cercy C, Boudieu L, Schopp J, Lazdunski M, Eschalier A, Lolignier S, and Busserolles J
- Subjects
- Animals, Male, Humans, PC-3 Cells, Mice, Cell Survival drug effects, Prostatic Neoplasms drug therapy, Prostatic Neoplasms pathology, Prostatic Neoplasms metabolism, Cell Line, Tumor, Riluzole pharmacology, Potassium Channels, Tandem Pore Domain metabolism, Bone Neoplasms drug therapy, Bone Neoplasms metabolism, Bone Neoplasms secondary, Bone Neoplasms pathology, Bone Neoplasms complications, Cancer Pain drug therapy, Cancer Pain metabolism, Mice, SCID, Analgesics pharmacology, Cell Proliferation drug effects
- Abstract
Background: The metastasis of tumors into bone tissue typically leads to intractable pain that is both very disabling and particularly difficult to manage. We investigated here whether riluzole could have beneficial effects for the treatment of prostate cancer-induced bone pain and how it could influence the development of bone metastasis., Methods: We used a bone pain model induced by intratibial injection of human PC3 prostate cancer cells into male SCID mice treated or not with riluzole administered in drinking water. We also used riluzole in vitro to assess its possible effect on PC3 cell viability and functionality, using patch-clamp., Results: Riluzole had a significant preventive effect on both evoked and spontaneous pain involving the TREK-1 potassium channel. Riluzole did not interfere with PC3-induced bone loss or bone remodeling in vivo. It also significantly decreased PC3 cell viability in vitro. The antiproliferative effect of riluzole is correlated with a TREK-1-dependent membrane hyperpolarization in these cells., Conclusion: The present data suggest that riluzole could be very useful to manage evoked and spontaneous hypersensitivity in cancer-induced bone pain and has no significant adverse effect on cancer progression., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Conflict of interest statement The authors have declared that no conflict of interest exists., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF